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Abstract
Background: We previously identified three short single peptides (P4, P6 and P7) representing different B-cell
epitopes on the extracellular domain of Her-2/neu for a vaccine that was tested in a phase-I clinical trial. Here we
describe the improvement of the multi peptide vaccine by fusing the single peptides to a hybrid peptide P467.
Methods: After coupling to either virosomes or to diphtheria toxoid CRM197 (CRM), the hybrid peptide was tested
in different concentrations in combination with either Montanide or Aluminium hydroxide (Alum) in preclinical
studies.
Results: Already low amount (10 μg) of P467 conjugated to CRM led to faster onset of high antibody levels
compared to the P467-virosome. The formulation P467-CRM-Montanide induced higher serum IgG antibody titers,
compared with P467-CRM-Alum, as examined by ELISA using recombinant Her-2/neu or Her-2/neu natively
expressed on the tumor cell line SK-BR-3. Compared to P467-CRM-Alum, higher in vitro production of IL-2 and IFNγ
in the Montanide-immunized mice was induced after re-stimulation of splenocytes with CRM but also with P467,
indicating a clear Th1-biased response. In contrast to the single B cell peptides, the hybrid peptide led to T cell
proliferation and cytokine production as CD4 T cell epitopes were generated in the fusion region of the single
peptides P4 and P6 or P6 and P7. Additionally, a significantly higher proportion IFNγ-producing CD8+ T cells was
found in the P467-CRM-Montanide immunized mice, probably by Montanide-driven bystander activation.
Importantly, anti-P467 IgG antibodies exhibited anti-tumor properties and the combination of anti-P467 specific IgG
with Herceptin® was found to inhibit the proliferation of Her-2/neu-overexpressing cell line SK-BR-3 in a significantly
higher capacity than Herceptin® alone.
Conclusions: Fusion of the B cell peptides has led to additional generation of CD4 T cell epitopes, and this
P467-multi epitope vaccine was found to induce polyclonal antibody responses with anti-proliferative capacity
against Her-2/neu. The hybrid vaccine together with Montanide induced higher and long-lasting antibody levels,
Th1-biased cellular responses being superior to vaccination with the single B cell peptides. This vaccine formulation
is now planned to be evaluated in a phase Ib/II study in Her-2/neu overexpressing cancer patients.
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Background
The 185 kDa transmembrane receptor oncoprotein Her-
2/neu, known also as ErbB-2, is a member of the ErbB/
epidermal growth factor receptors and class I family of
receptor tyrosine kinases [1]. The oncoprotein has been
shown to be involved in tumor progression, over-
expressed on tumor cells of e.g. breast and gastric
cancers, and also associated with poor disease outcome
[2]. Therefore Her-2/neu represents an excellent target
for the development of therapeutic agents [3].
Peptide-based vaccines offer several advantages, including
focusing the immune response to relevant epitopes and
avoiding non-protective responses, potentiating their use
for cancer immune-therapy [4, 5]. In line with this ap-
proach, our group has earlier identified three single pep-
tides with B cell peptides located in different regions of the
extracellular domains of Her-2/neu, i.e. P4, P6 and P7 [6].
We demonstrated that immunization with the single pep-
tides led to induction of antibodies with the capacity to in-
hibit tumor-growth in vitro, as shown by proliferation
assays, complement dependent- and antibody dependent-
cell cytotoxicity assays [6]. In a breast cancer mouse model
with activated c-neu oncogene, we further demonstrated
that immunization with the mixture of the three peptides
each coupled to tetanus toxoid elicited anti-tumor efficacy.
Co-application of the vaccine with IL-12 was associated
with a Th1-polarized immune response which demon-
strated elevated Her-2/neu-specific IgG levels and increased
in vitro production of IFNγ by splenocytes [7].
Virosomes, with an intrinsic adjuvant activity, support
antibody formation and induction of T-helper cell re-
sponses against surface-associated antigens and have
been used in human vaccines against e.g. influenza or
hepatitis A [8, 9] showing strong immunogenicity.
Accordingly, for clinical use, our multi-peptide vaccine
containing the single peptides conjugated to virosomes
was examined in a phase I study with breast cancer
patients in end stage of the disease [10]. While the study
showed good immunogenicity as well as an excellent
safety profile [10], several drawbacks of the virosomal
formulations including solubility and limited stability
after coupling all the single peptides together to viro-
somes, were the reasons to reconstruct and improve the
multi-peptide vaccine with respect to specificity and
clinical applicability. One possibility was to fuse the
three single peptides into one long hybrid peptide [11].
Different combinatorial orders of the single peptides
were therefore constructed and tested [12], eliciting two
candidate hybrid peptides as potentially immunogenic,
designated as P467 and P647.
The carrier protein CRM197 (CRM; Cross Linking Mate-
rials) is an enzymatically inactive and nontoxic [toxoid]
form of diphtheria toxin [13], and has been successfully
used in many vaccines against infectious diseases [14].
CRM rapidly activates CD4+ T cells with a heterogeneous
Th1 and Th2 cytokine profile for activating B cells and
regulating the quantity of the induced antibodies [15], and
therefore provides an alternative conjugation partner for
the peptides over virosomes. Additionally, the use of adju-
vants with Th1-promoting properties has been shown to be
of importance to enhance antitumor effects and reduce
vascularization within various tumor microenvironments
[16, 17]. The aim of the current study was therefore to
compare the immunogenicity of the selected hybrid peptide
in mice, 1) when coupled to CRM compared to virosomes
to select a potent carrier for the hybrid peptide vaccine,
and 2) when administered together with Montanide (a Th1
driving adjuvant, with capacity to induce both antibody and
cellular responses) [18] or Alum (a Th2 driving adjuvant)
[19] to select an adjuvant which gives more potent immune
responses with anti-tumor effects. Our results show that
the peptide conjugated to CRM promotes induction of
antibody responses, and in addition to humoral responses
also cellular responses are induced at significantly higher
levels with lower amounts of the peptide conjugate when
administered together with Montanide in contrast to Alum.
Methods
Peptides
For immunization studies, the single peptides P4
(PESFDGDPASNTAPLQP), P6 (RVLQGLPREYVNARH
C) and P7 (YMPIWKFPDEEGAC) [6, 7] were used to
construct the hybrid peptides P467 (PESFDGDPASNT
APLQPRVLQGLPREYVNARHSLPYMPIWKFPDEEGAC)
and P647 (RVLQGLPREYVNARHSPESFDGDPASNTAPL
QPYMPIWKFPDEEGAC) which were designed at Pevion
(Switzerland) and synthetized at Bachem (Switzerland);
during the synthesis of P467 and P647, the Cysteine (C) of
P6 was replaced by ‘SLP’ or ‘S’, respectively, as underlined.
In the immunization experiment-I both hybrid peptides
were coupled to either virosomes or to CRM (Mymetics,
The Netherlands), and in experiment-II the hybrid peptide
was only coupled to CRM (piCHEM, Austria). Of import-
ance to indicate that after conjugations, the P647-CRM
conjugate precipitated whereas P467-CRM remained sol-
uble in water-based buffer. To evaluate antibody responses
directed to the fusion peptides, non-conjugated P467 and
P647 were used as coating antigen.
For T cell epitope mapping, a panel of 20 overlapping
peptides spanning the entire sequence of the hybrid pep-
tide P467, each with 12 aa length and offset of 2 aa, as
well as each of the single peptides (Cambridge Research
Biochemicals Limited, Cambridge, UK), were used.
Adjuvants
The hybrid peptides P467 and P647, conjugated to either
CRM or virosomes, were examined with two different ad-
juvants, namely Alum (Aluminium hydroxide; Brenntag,
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Denmark/ Serva, Germany), or Montanide ISA-51-VG
(Seppic, France) which is a water-in-oil emulsion. The
amounts of the adjuvants were calculated based on the
amounts of the peptides administered in the immuniza-
tions. The mixing of P467-CRM with Montanide, using
2-syringe mixing method, or Alum adjuvants was carried
out according to the manufacturers’ instructions. The
adjuvants, mixed with NaCl (Montanide) or PBS (Alum),
were used as controls.
Mice immunizations
Female Balb/C mice (Charles River, Sulzfeld, Germany;
6–8 week of age at the time of delivery) were used in two
subcutaneous immunization studies, i.e. experiment-I
(Fig. 1a) followed by experiment-II (Fig. 1b). The experi-
ments were approved by the Animal Experimentation
Committee of the Medical University of Vienna and the
University of Veterinary Medicine as well as by the
Austrian Federal Ministry of Science and Research
(BMWF-66.009/0203-WF/V/3b/2015).
In experiment-I (5 mice per group), aiming to com-
pare virosomes and CRM as carriers, the immunizations
with conjugated constructs started 16 days after the
priming. All virosomal formulations were delivered
ready to use and were applied without any additives.
CRM-conjugates stocks were diluted with NaCl solution
and mixed with Alum prior injection. Of note, that P647
conjugated to CRM precipitated while no precipitation
of the P467-CRM conjugate was observed. CRM-P647
was vortexed and the suspension was used in the same
manner as CRM-P467. Four immunizations were given
in 3 weeks intervals, and blood samples were taken prior
each immunization and three weeks after the last
immunization when the mice were sacrificed.
In the follow up experiment-II (8 mice per group),
aiming to compare Alum and Montanide as adjuvants,
three immunizations were given in 3 weeks intervals,
and blood samples were taken prior the first and third
immunization, as well as three weeks after the last
immunization. In addition, for examining the kinetic of
the immune responses, additional blood samples were
taken in two months intervals for the period of 6 months
after the last immunization.
Detection of peptide-specific serum IgG
Microtiter plates (Nunc Maxisorp, Denmark) were
coated with uncoupled peptides P467 or P647 (Bachem,
Switzerland), in carbonate buffer (0.5 μg/well), and
ELISA was performed as previously described [6]. After
blocking, diluted sera from the immunized mice were
added. Bound IgG were detected with HRP-labelled
rabbit anti mouse IgG antibody and subsequent TMB
staining. For detection of IgG1 and IgG2a isotypes, rat
anti mouse IgG1 or rat anti mouse IgG2a (BD Biosci-
ences, USA) and the secondary antibody HRP-labelled
mouse anti-rat IgG (Jackson Immuno Research, USA)
were used, followed by TMB staining. Plates were read
after adding stop solution at 450 vs 630 nm.
Detection of Her-2/neu-specific IgG
A fusion protein consisting of the recombinant extracel-
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Bleedings for examining the kinetic of
serum antibody responses
Immunizations included:
1. Empty virosomes with Alum
2. P467-virosomes (30 µg) with Alum
3. P467-CRM (30 µg) with Alum
Immunizations included:




5. P467-CRM (10 µg, 25 µg or 50 µg) with Alum 
6. P467-CRM (10 µg, 25 µg or 50 µg) with Montanide
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Experiment-I: Comparison of CRM and virosomes as carrier proteins
Experiment-II: Comparison of Montanide and Alum as adjuvants
Fig. 1 Experimental design. Female Balb/C mice were immunized with different amounts of P467 and P647 hybrid peptides, conjugated to either
CRM or virosomes (1a; Experiment-I), or with different amounts of P467-CRM administered together with Alum or Montanide (1b; Experiment-II).
For examining the kinetic of the immune responses, additional blood samples were taken in two months intervals for the period of 6 months
after the last immunization. The occasions for immunization (black arrows) and bleeding (grey arrows) are indicated
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Fc region of human IgG1 (ErbB2/Fc Chimera, R&D Sys-
tems) was used as coating antigen. Plates were coated
with 0,1 μg/well, and detection of Her-2/neu specific
IgG antibodies as well as subclasses IgG1 and IgG2a was
carried out as described above.
Cytokines production in cultures of splenocytes
Mice (n = 4/group) immunized with P467-CRM construct
and administered with Alum or Montanide (experiment-
II), were sacrificed 18 days after the third immunization.
Splenocytes were taken aseptically, minced, sterile-filtered
and cell suspensions were prepared as previously de-
scribed [20]. Cells (5 × 105 per well) were plated in 96-well
round-bottomed plates, and stimulated with medium
alone, CRM, or unconjugated P467 at concentration of
20 μg/ml for 72 h in culture medium (RPMI 1640, with
10% heat- inactivated FCS, 2 mM L-Glutamine) at 37 °C,
95% humidity and 5% CO2. Supernatants were harvested
and stored at −20 °C, until analysis. Levels of secreted
IL-2, IFNγ and IL-5 were measured by ELISA according
to manufacturer’s instructions (Affymetrix eBioscience,
USA), and expressed in pg/ml.
Surface marker staining of lymphocyte populations by
FACS analysis of splenocytes
Freshly isolated splenocytes (1 × 106 cells) were stained for
characterization of lymphocytes sub-populations, i.e. T
cells (CD3 + CD4+ and CD3 + CD8+), B cells (CD3-CD19
+) and NK cells (CD3-CD335+), using fluorochrome-
conjugated antibodies CD3 FITC, CD4 PerCP, CD8a
(Ly-2) PE, CD19 APCeFluor780 and CD335 (NKp46)
eFluor450 (eBioscience). Pooled samples (per group) were
used as negative and FMO (Fluorescence Minus One)
controls in addition to Isotype controls.
Surface staining of Her-2/neu overexpressing cell line by
FACS analysis
The Her-2/neu-overexpressing human breast cancer cell
line SK-BR-3 and the human melanoma cell line 518.A2
as control cells (Her-2/neu negative) [6] were used to
evaluate the binding capacity of the sera raised against
the P467-CRM-Alum or P467-CRM-Montanide (experi-
ment-II). Cells were cultivated as described previously
[6], resuspended in FACS buffer and blocked with
human Ab serum. Antibody binding of the examined
mice sera, and Herceptin® (a humanized IgG1 antibody),
were detected with PE-conjugated secondary F(ab’)2
Anti-mouse IgG and Anti-Human IgG (Fc gamma-
specific) (eBioscience), respectively.
Intracellular staining of IFNγ production by single cell
analysis
Freshly isolated splenocytes (2,5 × 106 cells/ml in 24 flat
bottom well plate) were stimulated for 2 h at 37 °C, with
PMA (Sigma; Phorbol Myristate Acetate, 10 ng/ml) and
Ionomycin (Sigma; 1,25 μM), and additional 4 h with
Brefeldin A (Sigma; 10 μg/ml) to avoid secretion of cyto-
kines. Cells were then split into micronic tubes (1 × 106/
cells per tube), blocked with Fc Block (anti-mouse
CD16/32) and used for surface staining of CD3, CD4,
CD8, CD19 and CD335, using the above mentioned
fluorochrome-conjugated antibodies. Cells were then
fixed and permeabilized, followed by intracellular stain-
ing with IFNγ using fluorochrome-conjugated antibodies
IFNγMaB APC, and acquired on FACS Canto and
analyzed with CellQuestPro Software (BD).
T cell epitope mapping
Splenocytes from the mice immunized with 25 μg of
P467-CRM with Montanide (i.e. experiment-II) were
prepared as mentioned above, added into 96-well round-
bottomed plates (2 × 105 per well) and re-stimulated
with the single peptides P4, P6 and P7, the hybrid pep-
tide P467 or each of the over-lapping peptides of P467
(2 μg/well), for 96 h. ConA stimulation was used as posi-
tive control. To determine T cell proliferation, the stimu-
lated cells in each well were pulsed with 0.5 μCi [3H]
thymidine (Perkin Elemer) for the last 16–18 h of stimu-
lation and incorporated 3H was measured using a liquid
scintillation counter for measuring the CPM (counts per
minute). The proliferative responses were expressed as
stimulation index (SI), where SI = CPM for test culture
divided by CPM for unstimulated cells (baseline level).
SI ≥ 2 was considered as the capacity of the examined
peptides to stimulate T cells.
Tumor cell proliferation inhibition assay
To examine the inhibitory capacity of P467-specific anti-
bodies on proliferation of the Her-2/neu-overexpressing
cell line SK-BR-3, or the cell line 518.A2 as control cells,
New Zeeland White rabbits were immunized according
to the protocol of the laboratory of Charles River (Châ-
tillon-sur-Chalaronne, France) and serum IgG antibodies
were isolated as described previously [7]. The capacity of
the purified P467-specific antibodies, Herceptin® alone,
or a combination of both, with 10 μg of each examined
antibody, was evaluated in vitro using [3H]-thymidine
proliferation assay as described above.
Statistical analyses
Longitudinal data were analyzed by mixed ANOVA
models with repeated measures and two group factors
(dosage and type of adjuvant). For grouped data two-
factor (dose and adjuvant) ANOVA was performed.
Comparison of each time point of dose level was per-
formed by linear contrasts. For IFNγ producing T-cells
the comparison of the two adjuvants was done by Stu-
dent’s t-tests with two-tailed p-values considered.
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ANOVA and linear contrasts of arcsine transformed data
were applied for analysis of the proliferation inhibition
results. Significant differences were indicated as P values
<0.05 (*), 0.001–0.01 (**) or <0.001 (***).
Results
CRM-conjugated hybrid peptides are superior over
virosomal conjugates in inducing high antibody
responses already after two vaccine administrations
To check the number of administered doses required for
induction of strongest and quickest antibody responses
against the hybrid peptides P467 or P647, mice were first
immunized with 30 μg of each peptide, conjugated to
either CRM or virosomes (Fig. 1a; experiment-I).
Already after administration of 2 doses, the titers of
serum IgG antibody against recombinant Her-2 were
shown to be significantly higher in mice immunized with
P467-CRM conjugate than with P467-virosomes (Fig. 2a).
After 4 immunizations both P467-conjugated formula-
tions induced comparable and high levels of serum IgG
responses (Fig. 2a). In an additional examination we fur-
ther compared the titers of IgG antibodies in sera of
mice previously immunized in three occasions with the
mixture of single peptides P4, P6 and P7 expressed on
virosomes, or the hybrid peptide P467 expressed on
virosomes, or with CRM-conjugated hybrid peptide
P467 administered together with adjuvant (Montanide)
(Fig. 2b). While no difference between single peptides
and the hybrid peptide with regards to their immuno-
genicity was observed, the immunogenicity of the CRM-
conjugated hybrid peptide was shown to be markedly
superior over virosomes (Fig. 2b). These results all
together indicated the superiority of CRM as a carrier
protein over virosomes, leading to not only to more rap-
idly induced but also to higher antibody titers with bind-
ing capacity to the recombinant extracellular Her-2/neu.
The hybrid peptide P647 conjugated to CRM, but not to
virosomes, induced similar higher immune responses as
P467-CRM conjugate already after two rounds of immu-
nizations (data not shown). However due to problems
with solubility of the P647 hybrid peptide it was decided
to focus on P467 and evaluate its immunogenicity in
mice in a follow up immunization (Fig. 1b; experiment-
II) in which the adjuvants Montanide and Alum were
examined and compared.
A lower dose of P467-CRM administered with Montanide,
compared to Alum, induces higher antibody responses
along with mixed Th1/Th2 profile
To evaluate the antibody responses induced by the
P467-CRM, mice were immunized with 10, 25 or 50 μg
of the conjugate, administered with either Alum or
Montanide. Three weeks after the last immunization,
the lowest dose of the conjugate (10 μg) was shown to
induce significantly higher antibody levels of IgG
(Fig. 3a), IgG1 (Fig. 3b) and IgG2a (Fig. 3c) against P467
when administered with Montanide, compared to mice
administered with Alum or sham-induced control
groups. Her-2/neu specific IgG (Fig. 3d) and IgG1
(Fig. 3e) antibody responses were also significantly
higher in Montanide than Alum-immunized mice. The
anti-Her-2/neu IgG2a antibody titers in mice immunized
with 10 μg and 25 μg of the P467-CRM and Montanide
were also significantly higher than when compared to
Alum (Fig. 3f ). These results indicated that administra-
tion of only 10 μg of the P467-CRM conjugate with
Montanide can induce significantly higher Th1-polarized
antibody responses than the higher dose (50 μg) of the
peptide-conjugate administered with Alum.
To further evaluate if the antibodies induced by P467-
CRM-Montanide or with P467-CRM-Alum bind to na-
tive Her-2/neu, sera of the immunized mice were used
for staining of Her-2/neu overexpressing breast cancer






















































































































Fig. 2 Level of serum IgG antibody responses against recombinant
extracellular Her-2/neu. a Kinetic of the antibody responses induced
after 2, 3, and 4 immunizations with 30 μg of the hybrid peptide P467
conjugated to virosomes or CRM, are shown. b Comparison of the
levels of the antibody responses induced after 3 immunizations with
virosomal constructs expressing a mixture of single peptides (10 μg or
25 μg), virosomal constructs expressing the P467 peptide (15 μg or
30 μg), or the CRM-conjugated P467 administered together with
Montanide (10 μg or 25 μg) is shown. The OD values are based on
ELISA experiments as described in materials and methods. The
statistical analysis was performed using ANOVA (two-way) and linear
contrasts. Significant differences are denoted by asterisks
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518.A2 as control cells (Her-2/neu negative), and ana-
lyzed by FACS. Considerably higher number of SK-BR-3
cells was detected in case of sera raised against P467-
CRM-Montanide, when compared to P467-CRM-Alum
(Table 1). Marginal to undetectable number of SK-BR-3
cells was stained with the sera of mice before the immu-
nizations, or when the control cells 518.A2 were exam-
ined with sera against either the formulations, indicating
the binding specificity of the antibodies (Table 1). These
results not only show the higher antibody titers induced
by the sera against P467-CRM-Montanide, as observed
by ELISA assay, but also their similar binding capacity to
the recombinantly produced Her-2/neu and to the
Her2/neu natively expressed on the SK-BR-3 cells.
The kinetic of the serum IgG responses for a period of
six months after the last immunization was also exam-
ined. Compared to Alum, at all examined time points
and during the course of the examined period, signifi-
cantly higher IgG responses against P467 in mice admin-
istered with Montanide were observed (Fig. 4).
Accordingly, also higher Her-2/neu specific IgG re-
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Fig. 3 Levels of serum IgG, IgG1 and IgG2a antibody responses against P467 and recombinant extracellular Her-2/neu. The levels of serum IgG,
IgG1 and IgG2a against P467 (3a, 3b and 3c) or recombinant extracellular Her-2/neu (3d, 3e and 3f), induced after 3 immunizations with different
concentrations of the conjugate administered with Alum or Montanide, are shown. The OD values are based on ELISA experiments as described
in materials and methods. The statistical analysis was performed using ANOVA (two-way) and linear contrasts. Significant differences are
denoted by asterisks. ns, not significant
Table 1 Binding mice sera, immunized with P467-CRM-Alum or
P467-CRM-Montanide, to positive or negative Her-2/neu-overex-
pressing cell lines
Percentage of detected examined cellsa




P467-CRM-Alum (10 μg) 16 3.3
P467-CRM-Alum (25 μg) 6.9 1.8
P467-CRM-Alum (50 μg) 5.6 1.4
P467-CRM-Montanide (10 μg) 21.6 6.2
P467-CRM-Montanide (25 μg) 46.4 3.7
P467-CRM-Montanide (50 μg) 17.6 2.4
aThe values indicate the percentage of the stained Her-2/neu overexpressing
SK-BR-3 cells and 518.A2 cells as control cells (Her-2/neu negative) cells,
detected by FACS analysis, as described in material and methods. The sera
were diluted 1/100
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significant difference between the decline rate of the
responses was found (data not shown), the results indi-
cate the long term immunogenicity of the P467-CRM-
Montanide formulation.
Immunization with P467-CRM administered with Monta-
nide, compared to Alum, induces higher in vitro produc-
tion of IL-2, IFNγ and IL-5 upon re-stimulation with CRM
and P467
Splenocyte cultures from mice immunized with P467-CRM
together with Alum or Montanide were re-stimulated and
examined for in vitro cytokines production. Production of
IL-2, IFNγ and IL-5 (Fig. 5a, b and c, respectively) was
shown to be significantly higher after stimulation with
CRM in mice administered with Montanide, compared to
Alum. Interestingly, the cytokine production was also ob-
served upon re-stimulation of the splenocytes with the hy-
brid peptide P467 (Fig. 5d, e and f), indicating formation of
a T cell epitope after fusion of the single B cell epitopes
peptides in P467 with capacity to stimulate splenocytes.
T-cell epitope-mapping of P467
Based on the observation that the hybrid peptide P467 has
induced in vitro production of cytokines after re-
stimulation of splenocytes (Fig. 5d–f ), splenocytes of mice
which had been immunized with 25 μg of P467-CRM plus
Montanide were re-stimulated with P467 or individually
with each of the single peptides P4, P6 or P7. Comparing
the stimulation index (SI) values, the hybrid peptide led to
marked stimulation of splenocytes as compared to the sin-
gle (B cell) peptides (Fig. 6). To identify the T cell immu-
nodominant regions in P467, epitope mapping was carried
out by re-stimulating splenocytes of mice which had been
immunized with 25 μg of P467-CRM plus Montanide,
with series of overlapping peptides spanning the entire se-
quence of P467. Comparing the SI values (SI > 2), three
overlapping peptides were identified as potential
immunodominant CD4 T cell epitopes:
NTAPLQPRVLQG, SLPYMPIWKFPD and MPIWKFP-
DEEG, corresponding to the aa 11–22, 33–44, 37–47 of
P467, respectively, were identified (Table 2). These results
clearly indicated that the fusion of the single peptides has
generated novel T cell epitopes in the hybrid peptide with
T cell proliferative capacity of the hybrid peptide in con-
trast to the single B cell epitope peptides.
Montanide propagates expansion of IFNγ-producing CD8
T cell
The capacity of Montanide versus Alum in expanding
lymphocytes’ subpopulations, in particular IFNγ produ-
cing CD4 and CD8 T cells, was further evaluated by
FACS analyses on splenocytes of mice sacrificed three
weeks after the last immunization. The results indicated
expansion of T cells, of both CD4, CD8, as well as B
cells and NK cells in all examined groups (data not
shown). Since immunization with 25 μg of the hybrid
peptide plus Montanide was associated with the higher
cytokine responses, we further evaluated at single cell
level the IFNγ production by splenocytes of mice immu-
nized with 25 μg of P467-CRM administered with either
Alum or Montanide. The results showed IFNγ-
producing CD8 T cells in significantly higher levels espe-
cially in mice administered with Montanide rather than
with Alum (Fig. 7). IFNγ production by CD4 T cells and
NK cells did not differ between the groups (data not
shown). These results indicated enhanced capacity of
Montanide versus Alum to propagate the expansion of
different splenocyte subclasses, particularly of IFNγ-
production CD8 T cells.
Anti-tumor activity of induced antibodies
To assess the proliferation (tumor growth) inhibition































Fig. 4 Kinetic of serum IgG antibody responses against P467. The levels of serum IgG antibody responses, induced 2, 4 and 6 months after the
last immunization with different amounts of P467-CRM conjugate administered with Alum or Montanide, are shown. * The mice in this group
were sacrificed before the six-month period, and their splenocytes were used for the T cell epitope mapping analysis (Table 2). The OD values are
after subtraction of the background (i.e. pre-immunized mice), and based on ELISA experiments as described in materials and methods. The
statistical analysis was performed using Generalized Estimation Equations. Significant difference is denoted by ***
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purified P467-specific IgG antibodies were tested in vitro
using [3H]-thymidine proliferation assay with Her-2/neu
overexpressing SK-BR-3 cells. Incubation of SK-BR-3
cells with P467-IgG antibodies led to reduction of tumor
cells proliferation compared to untreated SK-BR-3 cells,
which was more pronounced (not significant) when cells
were incubated with Herceptin® (Fig. 8). However, com-
bining the examined purified IgG antibodies with Her-
ceptin® showed a significantly higher proliferation
inhibition than Herceptin® alone (Fig. 8), indicating the
additive effect of the P467-specific IgGs to Herceptin® in
inhibiting the growth of the examined Her-2/neu over-
expressing tumor cells. Neither Herceptin® nor the anti-
P467 antibodies in combination with Herceptin® led to
reduction of tumor growth of the Her-2/neu negative
tumor cell line (518.A2), showing the specificity of the
anti-tumor activities of the tested antibodies.
Discussion
We previously demonstrated that the 3 selected B cell
peptides of Her-2/neu, P4, P6 and P7, conjugated to
immune-stimulatory virosomes gave rise to Her-2/neu
specific antibodies with antitumor activity [6, 7]. Despite
an excellent safety and immunogenicity profile tested in
a phase-I study [10], problems of solubility and limited
stability of the formulation after coupling of the single
peptides to virosomes, were the reasons to improve the
formulation of the multi-peptide vaccine. Therefore, the
three single peptides were fused to each other to a long












































































































Fig. 5 Levels of cytokines, IL-2, IFNγ and IL-5, produced in vitro. Levels of IL-2, IFNγ and IL-5 produced in vitro in splenocytes of mice immunized
with different amounts of P467-CRM conjugate administered with Alum or Montanide, after re-stimulation with CRM (5a, 5b and 5c) or P467 (5d,
5e and 5f), are shown. Splenocytes of the immunized mice were used and re-stimulated, as described in materials and methods. The statistical
analysis was performed using ANOVA (two-way) and linear contrasts. The measured levels of the controls (Alum Montanide and CRM) in Fig. 5d










Hybrid peptide P467 P4 P6 P7





Fig. 6 T cell stimulation capacity of the hybrid peptide P467 and
single B cell epitope peptides. Splenocytes of mice immunized with
25 μg of P467-CRM together Montanide were re-stimulated with the
hybrid peptide P467 or the single B cell epitope peptides P4, P6 and
P7, as described in materials and methods. The bars indicate
stimulation indexes (SI) in the presence of each examined peptide.
The horizontal line indicates the cut-off of 2.0, above which the
calculated values of SI were considered as significant
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hybrid peptide, and in this study the immunogenicity of
the hybrid peptide was investigated.
The feasibility of the mutated diphtheria toxoid CRM as
a carrier protein, and as an alternative to virosomes, was
first tested after conjugation with the two examined hy-
brid peptides containing the single peptides fused in dif-
ferent combinatorial orders, i.e. P467 and P647. Already
after 2 immunizations, the CRM-conjugated hybrid pep-
tides were shown to induce significantly higher serum
antibody responses against Her-2/neu compared to the
virosome-based formulations. We further showed similar
capacity of the single peptides and the hybrid peptide
when expressed on virosomes in inducing anti-Her-2/neu
serum antibody responses, and CRM-conjugation of the
hybrid peptide was shown to markedly increase the
antibody titers indicating the superiority of the CRM ra-
ther than virosomes as carrier protein for conjugation of
the hybrid peptide. The rapid antibody responses shown
by the CRM-conjugates may be of importance in clinical
settings as additional to chemotherapy effects, and early
onset of immune responses is important for translation
into antitumor responses. This further signifies the advan-
tage of CRM over the virosome as a suitable carrier
protein for our hybrid peptides. Based on the observed
rapid immune responses with CRM, and precipitation
issues with the hybrid peptide P647, the P467-CRM con-
jugate was chosen for further investigation in a standard
immunization regimen (Fig. 1b; Experiment II,).
In addition to humoral responses induced by the hy-
brid peptide P467, in vitro re-stimulation of splenocytes
Table 2 T cell epitope mapping of the hybrid peptide P467
aThe positions of the single B cell epitope peptides P4, P6 and P7 are indicated under the sequence of the hybrid peptide P467. The amino acids SLP, which were
added during the fusion of P6 and P7, are shown in bold
bValues indicate the stimulation indexes measured after stimulation of mice splenocytes with the examined overlapping peptides, as described in materials and
methods, and are representative of two sets of experiments. The overlapping peptides with SI above 2 are highlighted
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with the peptide induced high levels of IL-2, IFNγ and
IL-5 production. This is of particular interest, as the sin-
gle peptides P4, P6 and P7 had been identified as B cell
epitopes with no capacity to stimulate T cells, suggesting
that fusion of the single peptides has formed epitopes
recognized by T cells. This was verified by examining
splenocytes, re-stimulated by series of short (12 aa) over-
lapping peptides spanning the entire sequence of P467
or each of the single peptides. Indeed, the hybrid peptide
led to nearly 3-fold higher stimulation index than the
single peptides, and the immunodominant T cell epi-
topes were shown to be located at the regions where the
single peptides are fused. The third immunodominant
CD4 T cell epitope is within the single peptide P7. Since
the single peptide P7 was shown to stimulate splenocytes
in a considerably lower capacity than the hybrid peptide,
these results suggest that the significant T cell stimula-
tory effect of the epitope MPIWKFPDEEG is as a result
of fusion of the single peptide P7 to the adjacent part of
the hybrid peptide. In addition, detection of the
MPIWKFPDEEG epitope which resides in the single
peptide P7 may also suggest the specificity of the gener-
ated CD4 T cells in recognizing Her-2/neu. These results
together signify the antigen specificity of our CRM-P467
as a novel conjugated peptide, comprising the capacity
of not only inducing antibody responses by retaining the
B cell epitopes of the single peptides P4, P6 and P7, but
also stimulating T cell responses as a result of fusing the
single peptides. Therefore, the high antibody responses
as a consequence of proper T cell help seem to be trig-
gered with the hybrid peptide as well as via bystander
help of CRM-induced CD4 T cells.
Selection of appropriate epitopes and the use of a po-
tent adjuvant system have both been proposed to be
necessary for successful vaccination and generation of
Her-2/neu immunity (3). Furthermore, in patients with
advanced cancer a shift from Th1 to Th2 impairing the
cell-mediated immunity has been reported [21], while
lower recurrence rate and a longer disease-free survival
was seen in patients with Th1-dominant responses [22].
Alum is a Th2-driving adjuvant [23] and based on its
ability to enhance antibody production is widely used in
human vaccinations against vaccine-preventable
diseases, while Montanide is an emulsion adjuvant and
capable of inducing both humoral and cellular responses
and is increasingly used in recent cancer vaccine candi-
dates [24]. In this study we therefore compared the
immunogenicity of P467-CRM administered with either
Alum or Montanide in Balb/C mice which have also
been used in our previous preclinical studies evaluating
the immunogenicity of the peptide vaccine [6].
Although both adjuvants were shown to further in-
crease the antibody responses when administered with



























Fig. 7 Level of INFγ-producing CD8+ T cells. The proportions of
INFγ − producing CD8+ T cells in mice immunized with 25 μg of
P467-CRM conjugate administered with Alum or Montanide, are
shown. The statistical analysis was performed using t test. Significant
difference is denoted by asterisks
Fig. 8 Proliferation inhibition of SK-BR-3 cells in vitro. [3H]-thymidine
proliferation assay demonstrating the effects of purified anti-P467
rabbit IgG antibodies on the Her-2/neu-overexpressing human
breast cancer cell line SK-BR-3 and the human melanoma cell line
518.A2 as control cells (Her-2/neu negative). Data are expressed in
percentage of inhibition, based on the mean (+ SEM) of the tested
antibody isolates; cpm values of untreated wells were set to 100%.
Significant difference is denoted by *. ns, not significant
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against P467 hybrid peptide as well as the recombinant
extracellular Her-2/neu were significantly higher in all
mice groups immunized with Montanide (in all exam-
ined doses) compared to Alum. Our results also clearly
showed that already with the lowest tested concentration
(10 μg per dose) of the P467-CRM conjugate plus Mon-
tanide, the antibody titers were higher than compared
with the highest tested concentration (50 μg per dose) of
the formulation containing Alum, and indicated the
superiority of Montanide- over Alum-containing formu-
lation in eliciting IgG and IgG1 responses at any exam-
ined dose. The fact that already with low concentrations
of the hybrid plus Montanide high immune responses
are induced, is beneficial in terms of the manufacturing
process of the formulation, and further signifies the ad-
vantage of Montanide in our CRM-conjugate hybrid
peptide formulation. In addition, our results showed that
even six months after the last immunization the serum
IgG responses were higher in the groups of mice admin-
istered with Montanide than with Alum. Although com-
paring the decline rates of the responses showed no
significant difference between the groups immunized
with Montanide or Alum, our results suggest the poten-
tial of Montanide rather than Alum in inducing Th1-
polarized and long term humoral responses. Similar
results of higher antibody titers induced by P467-CRM-
Montanide formulation, compared with P467-
CRM-Alum, were observed both by ELISA assay using
the recombinant Her-2/neu as the coating antigen as
well as by FACS analysis examining the binding of the
sera to native Her2/neu overexpressed on SK-BR-3 cell
line, indicating the capacity of the strongly induced anti-
bodies by P467-CRM-Montanide in specifically binding
also native Her-2/neu. Examining the biological activity
of anti-P467 IgG antibodies in inhibiting the prolifera-
tion of Her-2-overexpressing cell line SK-BR-3, our re-
sults also indicate that the induced antibodies possess
specific anti-tumor properties and when combined with
Herceptin® the inhibitory capacity is significantly higher
than by Herceptin® alone suggesting polyclonal and addi-
tive anti-proliferative antibody responses against Her-2/
neu by our hybrid peptide P467.
As mentioned, for successful tumor prevention the
polarization of the immune response towards the Th1
type is highly important [3]. The Th1-produced
cytokines, primarily IFNγ and IL-2 are essential for in-
duction of cellular immunity, whereas Th2-produced
cytokines like IL-4, IL-5 and IL-10 play a key role in eli-
citing humoral responses [25, 26]. The effectiveness of
Th1 cells in the generation and maintenance of strong
immunological memory has been shown [27], as well as
association between secretion of IFNγ by CD4 T cells
and their anti-tumor effects, e.g. by reducing prolifera-
tion and angiogenesis and enhancing apoptosis of tumor
cells [28]. Further, effectiveness of IL-12 in inducing an-
titumor immunity in vivo through the activation of Th1
immunity has been demonstrated [26]; in agreement
with this, we have earlier shown increased efficacy of
our multi-peptide vaccine in reducing tumor growth in
Her-2/neu transgenic mice when immunized together
with IL-12, resulting in increased INFγ production and
supporting the attribution of Th1 biased immune
response to anti-tumor efficacy [7]. In the current study
we have shown that upon re-stimulation with either
CRM or P467, secretion of both IL-2 and IFNγ by sple-
nocytes of mice immunized with P467-CRM plus Mon-
tanide was higher compared to Alum-containing
formulation. Re-stimulation with the hybrid peptide
P467 also induced IL-5 production- preferably in Mon-
tanide immunized mice, however in lower amounts than
IL-2 and IFNγ. These results clearly indicate a Th1-
poloarized immune response induced by the conjugated
hybrid peptide administered together with Montanide.
Similar results of IFNγ-associated T cell responses were
also reported by Kenter et al. [29] when peptides of the
E protein from human papillomaviruses (HPV16) were
examined in conjugation with Montanide in a phase I
trial.
A significantly higher number of IFNγ-producing CD8
T cells was observed in mice immunized with 25 μg
peptide-CRM plus Montanide compared to mice admin-
istered with Alum. However it is unknown whether
these cells are peptide or carrier specific, suggesting the
possibilities that Montanide induces more efficient
cross-presentation of peptide or carrier on MHC-I to
CD8 T cells or that bystander activation of CD8 T cells
occurs. Previous studies have shown that the activation
of the desired IFNγ-producing CD8 T cells was as a
result of bystander activation [30–32], suggesting the
Montanide-driven bystander activation of the IFNγ-
producing CD8 T cells also in our study.
As an oil-based adjuvant, Montanide persists at sub-
cutaneous injection sites and formation of a depot effect
is believed to contribute to immune enhancement of the
adjuvant by slow release of the antigen associated with
the adjuvant. Inflammatory and lymphocyte-trapping
capacity of the adjuvant, by stimulating recruitment of
antigen presenting cells and accumulation of lympho-
cytes in draining lymph nodes, respectively, are also
involved in the immune enhancing effect of Montanide
[18]. The Montanide used in our study, i.e. ISA-5-VG,
contains vegetable-grade (VG) oleic acid derived from
olive oil, and it has recently been used in a phase-I clin-
ical trial enrolling patients with survivin-expressing solid
tumor [33]. The study has shown that all subjects expe-
rienced one or more treatment-emergent adverse effects
of general disorders, administration site conditions or
gastrointestinal disorders, however less frequent adverse
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effects were observed in the subjects receiving the lowest
dose (30 μg) and in overall the trial treatment was well
tolerated with local injection-site reaction being the
most frequent adverse effect [33]. In an additional phase
1/2a study, enrolling patients with advanced human
papillomavirus-associated cancers and using the ISA-
51VG adjuvant, mild injection site reactions were found
to be related to the study treatment while all reported
serious adverse events were unrelated to the study
treatment [34].
Conclusions
The results of this study show several advantages of the
evaluated CRM-conjugated hybrid peptide over the pre-
vious multi-peptide vaccine with B cell epitope peptides
individually conjugated to virosomes. Our novel CRM-
conjugated construct not only retains the B cell epitopes
of the single peptides with the capacity to induce anti-
body responses, the fusion of the single peptides has fur-
ther generated T cell epitopes in the hybrid peptide
capable of inducing cellular responses. When conjugated
to CRM, our selected hybrid peptide induces consider-
ably higher and more rapid immune responses
compared to the virosome-conjugated peptides, elicits
long-lasting antibody responses and exhibits antitumor
activity. Also administration of the CRM conjugate with
Montanide, compared to Alum, induces not only CD4
Th1-driven responses but also IFNγ-producing CD8 T
cells already in the lowest concentration of the dose.
Taken together, these results suggest the potential of our
novel formulation containing CRM-P467 plus Monta-
nide as a vaccine against Her-2/neu with polyclonal anti-
tumor effect. The formulation P467-CRM-Montanide
has recently been examined in a toxicology study and
shown no signs of toxicity or inflammation when evalu-
ated in dogs and rats (data not shown). A dose-
escalating study, starting with 10 μg of the formulation,
is being planned to be evaluated in a phase-Ib/II clinical
trial enrolling Her-2/neu overexpressing cancer patients.
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